Top Page
Tristel
(LSE:TSTL)
Tristel (TSTL) vs. iShares MSCI United Kingdom ETF (EWC)
Tristel Business Overview & Revenue Model
Tristel Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 41.93M | 36.01M | 31.12M | 31.00M | 31.68M |
| Gross Profit | 30.87M | 29.18M | 24.66M | 24.74M | 25.25M |
| EBITDA | 10.01M | 7.84M | 4.46M | 6.70M | 9.30M |
| Net Income | 6.49M | 4.46M | 987.00K | 3.66M | 5.10M |
Balance Sheet | |||||
| Total Assets | 44.11M | 41.37M | 38.74M | 39.93M | 40.93M |
| Cash, Cash Equivalents and Short-Term Investments | 11.79M | 9.54M | 8.88M | 8.09M | 6.21M |
| Total Debt | 5.86M | 5.18M | 5.81M | 5.91M | 6.00M |
| Total Liabilities | 11.70M | 10.68M | 9.75M | 9.85M | 12.47M |
| Stockholders Equity | 32.41M | 30.68M | 28.98M | 30.08M | 28.46M |
Cash Flow | |||||
| Free Cash Flow | 10.06M | 6.07M | 4.35M | 4.71M | 4.61M |
| Operating Cash Flow | 11.20M | 8.49M | 5.55M | 6.48M | 6.99M |
| Investing Cash Flow | -5.40M | -4.84M | -1.20M | -1.77M | -2.97M |
| Financing Cash Flow | -6.57M | -5.44M | -3.62M | -2.83M | -2.02M |
Tristel Technical Analysis
Tristel Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | £190.85M | 30.98 | 19.61% | 4.22% | 10.32% | 1.25% | |
81 Outperform | £202.83M | 5.58 | 33.70% | 1.52% | -0.17% | 2591.96% | |
75 Outperform | £117.66M | 18.84 | 8.95% | 4.80% | -4.59% | 165.38% | |
71 Outperform | £5.55B | 37.36 | 11.12% | 2.01% | 3.94% | 41.63% | |
66 Neutral | £440.12M | 61.63 | 2.93% | 1.04% | 40.66% | -55.09% | |
65 Neutral | £283.84M | 77.27 | 4.55% | 136.69% | 13.59% | -66.27% | |
51 Neutral | $7.55B | 0.30 | -61.90% | 2.27% | 17.11% | 1.58% |
Tristel Corporate Events
Tristel plc announced its successful participation at APIC 2025, the largest annual infection prevention and control conference in the U.S., where it launched Tristel OPH, a high-level disinfectant for ophthalmic instruments, following FDA clearance. The product addresses a significant unmet need in ophthalmology, generating strong interest and establishing a robust pipeline of prospective customers. Tristel also showcased its Tristel ULT disinfectant for ultrasound probes and the Tristel 3T digital traceability platform, both receiving positive reception. This event reinforces Tristel’s momentum in the U.S. market, highlighting the demand for innovative disinfection solutions.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £4.40 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc announced it will host two investor presentations on July 29 and 30, 2025, offering insights into its infection prevention products and operations. The company will also provide a trading update for the year ended June 30, 2025, on July 29, 2025. These events aim to engage institutional investors, analysts, and shareholders, reinforcing Tristel’s commitment to transparency and stakeholder engagement.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £4.40 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel PLC has announced a change in its major holdings, with Danske Bank A/S crossing a threshold in its voting rights. The notification indicates a decrease in Danske Bank’s voting rights from 3.06563% to 2.98208%, reflecting a shift in the company’s shareholder structure. This change could impact Tristel’s governance and decision-making processes, potentially influencing its strategic direction and stakeholder relationships.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £4.40 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc announced its participation in the Mello2025 investor event, where CEO Matt Sassone will present the company’s overview and strategy. The event provides an opportunity for Tristel to engage with investors, although no new information will be disclosed. This participation underscores Tristel’s commitment to maintaining transparency with stakeholders and highlights its strategic focus in the infection prevention industry.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £4.40 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc, a leader in infection prevention products, has issued 9,500 new ordinary shares following employee option exercises. These shares are set to commence trading on AIM on 19 May 2025, increasing the total number of voting rights to 47,711,843. This move allows shareholders to adjust their holdings in accordance with FCA’s rules, potentially impacting the company’s market positioning and stakeholder interests.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £4.40 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc announced the upcoming retirement of its Chief Financial Officer, Liz Dixon, effective June 30, 2025. Dixon has been instrumental in Tristel’s growth since joining in 2007, playing a key role in securing market access to North America and building a strong finance team. The company is in the process of appointing a new CFO and anticipates continued profitable growth under the leadership of CEO Matt Sassone and the senior team.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £4.40 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc has received FDA clearance for its Tristel OPH, a high-level disinfectant foam for ophthalmic medical devices, marking a significant advancement in the US market. This clearance allows Tristel to address the inefficiencies and safety concerns of existing disinfection methods, offering a faster and safer alternative that is compatible with widely used devices. The company has already established local manufacturing in the US and is poised to support early adopters, potentially transforming ophthalmic disinfection practices in North America.
Tristel plc has submitted additional information to the FDA for its Tristel OPH, a high-level disinfectant foam for ophthalmic devices, with an expected decision by June 2025. The approval could significantly impact ophthalmic disinfection practices in North America, addressing inefficiencies and improving safety standards. The company aims to leverage this opportunity to enhance its market presence and reach key decision-makers at the upcoming APIC conference.
Tristel plc announced the publication of a poster by the Mayo Clinic at the AORN Global Surgical Conference & Expo, detailing the successful trial of Tristel ULT™, a high-level disinfection foam for ultrasound probes. The trial, which involved 11 Mayo Clinic staff members and 189 ultrasound probes, reported no surgical site infections and highlighted the foam’s effectiveness, efficiency, and cost-effectiveness. This development follows recognition by the AAMI and ANSI of chlorine dioxide foam as a novel disinfection method and adds to the growing number of US case studies supporting Tristel ULT™. Tristel’s sales in North America are experiencing strong growth, with over 200,000 disinfection procedures conducted this financial year, reflecting increasing adoption and customer engagement.